sicklecellanemianews1d
Pfizer withdraws Oxbryta from global markets, cites safety concerns
Pfizer withdrew Oxbryta (voxelotor), a conditionally approved oral therapy for SCD, saying its benefits don't outweigh risks.
Pfizer starts voluntary withdrawal of OXBRYTA, benefit does not outweigh risks
The withdrawal comes after postmarketing studies showed that the risks of side effects were greater than the benefits.
BioSpace16h
BMS’ Schizophrenia Approval, Pfizer’s Sudden Sickle Cell Withdrawal and Roche’s Pharma Day
Bristol Myers Squibb wins approval for the first novel schizophrenia drug in decades; Pfizer pulls Oxbryta from the market; ...
FDA alerts patients about Pfizer's Oxbryta withdrawal
The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of ...
devdiscourse5d
Today’s Health Roundup: Schizophrenia Breakthrough and Bird Flu Vaccination Pressures
This health news roundup covers significant advances and alerts, including the approval of Bristol Myers' new schizophrenia ...
Yahoo Finance5d
Pharma Stock Roundup: JNJ's 3rd Talc-Related Bankruptcy Filing & More
Pfizer PFE said it is withdrawing its sickle-cell drug (“SCD”) drug, Oxbryta from worldwide markets. Merck’s MRK Keytruda ...
STAT5d
Biotech’s real estate market is still upside down
Medicare’s controversial decision to condition coverage for even fully approved Alzheimer’s drugs is here to stay, per a top ...
devdiscourse5d
Major Developments in Health Sector: New Drugs and Global Initiatives
The U.S. FDA approved Bristol Myers' new schizophrenia drug, the first of its kind in decades. Bavarian Nordic signed an ...